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Background: Seminomatous and non-seminomatous Germ Cell Tumors (GCT) of the testis are a rare cancer, with
an estimated incidence of 56.3 per million white males and 10 per million black males in the United States.
The association between non-seminomatous GCT and horseshoe kidney is a rare event and is seen in about 1.3%
of patients requiring retroperitoneal lymph node dissection. To our knowledge, no cases have been reported in
which replacement of the IVC was also necessary.
Case presentation: We report the case of a 22-year-old man with horseshoe kidney and metastatic non-seminomatous
germ cell tumor involving the wall of the inferior vena cava.
Following post-chemotherapy retroperitonal lymph node dissection, the inferior vena cava was replaced with an
expanded polytetrafluoroethylene graft.
At 2-years follow-up, the patient was in good health and the graft was patent. No clinical or diagnostic signs of renal
impairment or recurrence of neoplastic disease were noted.
Conclusion: Radical surgery is warranted in patients with non-seminomatous germ cell tumor metastasizing to the
retroperitoneal lymph nodes. When vena cava replacement is required, and the situation is further complicated by
horseshoe kidney, as in this case, surgical technique will rely on multidisciplinary surgical treatment planning by a team
composed of urologists, vascular surgeons and oncologists.
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Seminomatous and non-seminomatous Germ Cell Tumors
(GCT) of the testis are a rare cancer, with an estimated in-
cidence of 56.3 per million white males and 10 per million
black males in the United States. The annual incidence of
seminomatous GCT is about 32 cases per million and that
of non-seminomatous GCT about 27 cases per million [1].
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Testicular cancer is the most frequent type of testicu-
lar cancer in males between 20 and 35 years of age; the
5-year survival rate of seminomatous GCT is 72-80%
and that of non-seminomatous GCT is 48-92% depen-
ding on prognostic class [2]. The factors that have con-
tributed most to improving survival are accurate tumor
staging at diagnosis and appropriate early treatment
combining chemotherapy, radiotherapy (in seminoma-
tous GCT), surgery, and careful follow-up. With an ag-
gressive multimodality approach combining the use of
cisplatin chemotherapy and surgery, survival rates haveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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pending on initial extension of disease [3,4].
Surgery with either post-chemotherapy lymph node
dissection or residual tumor resection has become a main-
stay in the treatment of non-seminomatous GCT presen-
ting one or more residual masses after chemotherapy. As
post-chemotherapy surgery poses particular challenges
and often requires ad hoc vascular intervention, e.g., vena
cava or aortic graft replacement, patients should be re-
ferred to a specialized surgery center with expertise in
hepatic resection, vessel replacement, spinal neurosurgery,
and thoracic surgery. The benefit to patients treated at
such interdisciplinary centers is a significant reduction in
perioperative mortality from 6 to 0.8% [5] and local re-
currence from 16 to 3% and an overall higher rate of
complete resection when treated by a urologic surgeon [6].
The concurrent presentation of non-seminomatous
GCT with retroperitoneal metastasis involving the in-
ferior vena cava and horseshoe kidney, a congenital dis-
order, is a rare event that further complicates surgical
treatment of the tumor. To our knowledge, this is the
first such case to be reported.
Case presentation
A 22-year-old man underwent right radical orchiectomy
for a testicular mass; the histopathological diagnosis was
pure teratoma of the testis. Computed Tomography (CT)
with contrast material of the abdomen, chest and head for
tumor staging showed metastases to the liver, lungs, retro-
peritoneal lymph nodes, and brain. The imaging studies
also revealed a right laterocaval retroperitoneal mass
(largest diameter 7 × 9 cm) invading the iliopsoas muscle
but without clear signs of caval wall infiltration (Figure 1).
An incidental imaging discovery was a horseshoe kidney
with a parenchymatous isthmus. The level of Beta-Human
Chorionic Gonadotropin (BHCG) was 2,250,000 IU/L
(normal values < 5 IU/L in males) and that of alpha-
fetoprotein 2 ng/ml (normal values < 10 ng/ml in adult
males).Figure 1 Retroperitoneal right laterocaval mass. CT shows the coexiste
mass of the maximum diameter of 7 × 9 cm, indissociable from the iliopsoThe patient subsequently underwent three cycles of
chemotherapy with etoposide and cisplatin; a fourth cycle
of EP was suspended due to the occurrence of a bacterial
endocarditis. After the improvement of clinical conditions,
the patient underwent a salvage chemotherapy with four
cycles of etoposide, ifosfamide and cisplatin, during which
the BHCG level decreased to 86 IU/L. On Positron-
Emission Tomography (PET), elevated metabolic activity
was absent in the lung and liver lesions but present in the
laterocaval retroperitoneal lymph node mass.
On AngioCT prior to surgery for removal of the re-
sidual retroperitoneal mass, the mass (largest diameter
5-6 cm) was found to be continuous with the inferior
vena cava and extend to the inter-aorto-caval area. The
images also showed, besides the known horseshoe kid-
ney, two right renal arteries, one left renal artery, and
one renal vein on each side draining into the inferior
vena cava.
The retroperitoneal mass was removed via transperito-
neal surgical access. After a puboxiphoid incision and V
opening of the retroperitoneal cavity, the right side of the
horseshoe kidney and the two right renal arteries were
isolated. The retroperitoneal lymphatic mass (largest
diameter about 6 cm) was found to infiltrate the psoas
muscle and the lateral wall of the inferior vena cava along
its entire thickness for about 5 cm, from the segment
underneath the renal isthmus till 3-4 cm from the iliocaval
confluence (Figure 2).
The right external iliac lymph nodes, laterocaval, inter-
aortocaval and presacral lymph nodes were removed. The
right side of the horseshoe kidney was dislodged from the
posterior planes of the abdominal cavity, flipped supero-
medially en bloc with its vascular structures to expose the
mass (Figure 3). The lymph node mass infiltrating the
caval wall was removed (Figures 4, 5, 6, 7) and an approxi-
mately 10 cm long section of the inferior vena cava was
replaced with a ringed PTFE (PolyTetraFluoroEthylene)
graft (16 mm) (Figure 8). Anticoagulant therapy with low-
molecular weight heparin at the therapeutic dose wasnce of a horseshoe kidney (A) and a retroperitoneal right laterocaval
as muscle and without clear signs of infiltration of the caval wall (B).
Figure 4 The caval mass is dissected, but it infiltrates the psoas
muscle that is partially sectioned with the mass.
Figure 2 Horseshoe kidney and cava vein. The retroperitoneal
mass, of diameter of about 6 cm, was infiltrating the psoas muscle
and also the lateral wall of the cava vein that was interested in
full-thickness to about 5 cm of extension, from its portion below the
isthmus renal up to 3-4 cm from the ileo-caval confluence.
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prehending a small area of chondroid vital tissue for the
mass infiltrating inferior vena cava and psoas muscle.
All other resected lymph-nodes resulted negative.
Control CT at 1 month postoperative showed graft
and inferior vena cava patency, a reduction of about 20%
in the volume of the lung lesions as compared to the CT
scan obtained before chemotherapy, and no recurrence
of neoplastic abdominal tissue. The graft patency and
absence of abdominal neoplastic tissue was confirmed at
1 year AngioCT (Figure 9).
The patient then underwent removal of the brain me-
tastases secondary to GCT with choriocarcinomatous
features, followed by one cycle of chemotherapy withFigure 3 The caval lymph-node dissection begins. The right side
of the horseshoe kidney was dislodged from the posterior planes of
the abdominal cavity, flipped superomedially en bloc with its
vascular structures to expose the mass.paclitaxel, ifosfamide, and cisplatin. At 18 months the
patient underwent resection of bilateral lung lesions. At
2 years follow-up, the patients was in good health and
virtually disease free (normal value of tumor markers).
Control AngioCT confirmed transformation of the liver
lesions into cysts. The inferior vena cava and the graft
were both patent, and no signs of renal insufficiency
were noted. The patient is still under oral anticoagulant
therapy. Renal function was unchanged as compared to
pretreatment status.
Discussion
The International Germ Cell Cancer Collaborative
Group (IGCCCG) classifies GCT as a tumor having
good, medium, or poor prognosis on the basis of varia-
bles including primary tumor site, presence or absence
of metastases, levels of AFP (Alpha-FetoProtein), BHCG,Figure 5 During the dissection, an attempt to free the cava
vein from the mass is made, but the caval wall is massively
infiltrated by the lesion.
Figure 8 Cava prosthetic replacement. Removal of the mass
infiltrating the wall of the vena cava and inferior vena cava
replacement for a section of about 10 cm with a 16 mm ringed
PTFE prosthesis.
Figure 6 The segment of inferior vena cava infiltrated by the
mass is then removed.
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patient was classified as carrying a poor prognosis owing
to the presence of extrapulmonary lesions and the ex-
tremely high level of BHCG (2,250,000 IU/L) at diagnosis.
According to the guidelines of the European Association
of Urology (March 2011) and the National Compre-
hension Cancer Network (NCCN 2012), in cases of
non-seminomatous GCT treated with orchiectomy and
chemotherapy but with residual retroperitoneal lymph
nodes >1 cm, removal of the residual mass is warranted
and defined as “desperation surgery” in some cases [7,8].
Of fundamental importance is radical surgery [9], with ad
hoc vascular surgery procedures for caval and aortic re-
placement [4].
Recent studies have shown that about 7% of patients
who had received post-chemotherapy retroperitoneal
lymph node dissection will require resection of the IVCFigure 7 The operative field after the complete removal of the
residual mass, the inferior vena cava and a part of psoas
muscle.[10] because of tumoral infiltration into the cava. Re-
cently, Winter et al. evaluated 339 cases with an absolute
indication of residual tumor resection after chemother-
apy in patients with advanced stage GCT. Surgery of the
IVC was necessary in 34 patients (about 10%), in 56% of
which vena cava resection and graft placement were re-
quired. Resection and interruption of the IVC without
reconstruction is possible only in cases of previous caval
obstruction and the formation of collaterals which pro-
vide for sufficient venous drainage. No complications,
e.g., lower limb oedema, decreased renal function, de-
veloped in any of the patients undergoing graft recon-
struction of the IVC [11]. However, Gloviczki et al.
reported a 54% patency rate at 2 years after iliacocaval
reconstruction with PTFE grafts [12].
An alternative to grafting may be primary ligation of
the IVC without replacement of the removed segment;
however, this is associated with a higher post-operative
complications rate, a mortality rate of 9%, and severe
lower limbs oedema in 36% of cases. Symptoms secon-
dary to chronic venous insufficiency, including second-
ary varicose veins of the lower limbs, scrotum and
abdomen, have been reported in up to 50% of cases. A
recent study in 47 patients undergoing caval replace-
ment for infiltrating tumor showed that graft replace-
ment of the IVC prevents venous complications in the
extremities and probably contributes to improving qua-
lity of life and survival [13].
The IVC can also be replaced with autologous veins,
but this option is often impractical because of the diffi-
culty in harvesting enough homologous material to sub-
stitute a long venous segment. Spiral vein grafts are not
recommended owing to the elevated thrombogenicity of
the surface exposed at the suture sites and the high risk
of veins collapsing due to the positive intra-abdominal
Figure 9 Follow up imaging. The control CT at 1 year (A and B) demonstrates the absence of the lesion and the patency of the prosthesis.
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of choice for caval replacement, with ringed grafts best
able to prevent side effects during the immediate post-
operative period and symptoms of chronic venous insuf-
ficiency [10,15].
In the case presented here, caval replacement was car-
ried out in the context of a particular anatomic setting:
horseshoe kidney. Central fusion of the kidneys occurs
when the embryo is 5 to 12 mm, i.e., when the kidneys
lie in the true pelvis. Horseshoe kidney is usually located
between L3 and L5, lower than normal, because its
ascent is impeded by the root of the inferior mesenteric
artery. Also, its normal medial rotation is impeded, fre-
quently resulting in an anomalous course of the ureters,
which are often ectopic or retrocaval. The kidneys are
fused together by a thick isthmus, generally parenchy-
matous and very often situated anterior to the aorta and
the IVC. More rarely it may be found posterior to these
vessels or in the interaortocaval space.
The incidence of horseshoe kidney is between 1/400
and 1/800 persons, with a male-to-female ratio of about
2:1. In 90% of cases, the kidneys are fused at the lower
poles, either symmetrically (midline fusion) or asymme-
trically (L-shaped fusion) [16].
The vascular network of horseshoe kidney varies
widely:
1. One renal artery per side (20%)
2. One renal artery per side with a branch from the
aorta to the isthmus (30%)
3. Two arteries per side with an aortic branch to the
isthmus (15%)
4. Two arteries per side with one or more arteries from
the iliac arteries to the isthmus (15%)
5. Multiple renal arteries originating from the aorta,
the iliac and the mesenteric arteries (20%) [17]
Because embryogenesis of the kidney occurs contem-
poraneously with its venous drainage system in the venacava, there is a correlation between the presence of
horseshoe kidney and venous abnormalities:
1. Double IVC (0.2-3%)
2. Postrenal left IVC (0.2-0.5%)
3. Retroaortic left renal vein (2.1%)
4. Circumaortic left renal vein (8.7%)
5. Retrocaval or circumcaval ureters (0.001-0.1%)
6. Preaortic iliac vein confluence (very rare) [18]
The association between non-seminomatous GCT and
horseshoe kidney is a rare event and is seen in about
1.3% of patients requiring retroperitoneal lymph node
dissection [16]. To our knowledge, no cases have been
reported in which replacement of the IVC was also
necessary.
As described by Evans et al. [16] and Sogani et al., [19]
retroperitoneal lymph node dissection in patients with
horseshoe kidney demands scrupulous preparation be-
cause of the added complexities arising from the vascular
abnormalities associated with this congenital disorder.
Added to this is the need to avoid resecting the isthmus as
it is often composed of functional renal parenchyma and
is therefore richly vascularized. Only the resection of a
fibrous isthmus should not lead to a reduction in renal
function or to immediate complications such as bleeding.
Scheduled caval replacement will entail careful pre-
operative imaging to evaluate the morphology and func-
tionality of the isthmus of horseshoe kidney, its arterial
vascularization and anatomic relationships with the ure-
ters and venous structures. In young patients, the surgical
goal is to achieve radical removal. Winter et al. [11] re-
ported that, on the basis of univariate analysis, the residual
mass size (>5 cm) and the IGCCCG prognostic class were
predictive factors for completing residual tumor resection
in procedures involving the IVC (Inferior Vena Cava), thus
providing the basic parameters for surgical planning. Also
of fundamental importance is to minimize major he-
modynamic complication and preserve renal function.
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dures is burdened by high mortality, with survival rates of
about 71% due to the deteriorated physical condition of
patients who have undergone several cycles of chemo-
therapy [20,21].
Conclusions
Residual tumor removal is associated with high rates of
mortality and comorbidity. In patients with horseshoe
kidney and advanced stage non-seminomatous GCT
(NSGCT) and post-chemotherapy retroperitoneal re-
sidual disease amenable to resection, the aims of surgi-
cal treatment are to achieve radical tumor removal,
restore venous drainage, and preserve renal function
without worsening the precarious health of a patient
already severely debilitated by disease and treatment.
These objectives can be reached with scrupulous eva-
luation of the individual case by a multidisciplinary
team composed of an urologist, a vascular surgeon, and
a medical oncologist. Caval replacement with a ringed
PTFE should be performed without resecting the renal
isthmus, owing to the frequent vascular anomalies asso-
ciated with this disorder, and thus avoid the risk of
bleeding complications.
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